Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Despite mixed quarterly results and increased R&D expenses, optimism stems from strong growth in Skyrizi, Rinvoq, and promising segments like Neuroscience and Oncology. AbbVie's strategic move ...

AbbVie’s Skyrizi, a biologic approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, jumped from the 10th to fifth spot. The three that fell off the list ...